



**Media Contact:**

Andrew Chasteen  
Accelerate Diagnostics, Inc.  
+1 520 365-3100

FOR IMMEDIATE RELEASE:

**Accelerate Diagnostics shares performance data at AMMI/CACMID addressing  
The Accelerate Pheno™ system's potential influence on timely therapy decisions  
for patients with positive blood cultures.**

Eight poster presentations.

TUCSON, Arizona, USA, May 2, 2018 — Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that performance data will be presented during the Association of Medical Microbiology and Infectious Disease Canada/Canadian Association for Clinical Microbiology and Infectious Disease 2018 congress in Vancouver, Canada, May 2-5 at the Sheraton Vancouver Wall Centre.

Dr. Jennifer Grant BS, MD, CM (McGill University), and clinical associate professor and microbiologist at Vancouver General Hospital will present on Friday, May 4<sup>th</sup>, from 5:30 - 5:45 p.m. local time in the Junior Ballroom AB. Her presentation will focus on the Accelerate Pheno™ system's potential to influence timely therapy decisions for patients with positive blood cultures. Grant's presentation will be followed by a Q & A session.

In addition to Grant's presentation, there will be an additional 8 poster presentations about the Accelerate Pheno™ system featured on Friday, May 4 in the Grand Ballroom of the Sheraton Vancouver Wall Centre.

Accelerate Diagnostics' poster presentations are listed below:

SERIAL NO: 0242/PROG. NO: PF33 — *Improving time to blood culture identification and susceptibility results for remote hospitals using the Accelerate Pheno™ system.* Presented by Grant Johnson, administrative director of laboratory medicine at Lakeridge Health.

SERIAL NO: 0165/PROG. NO: PF44 — *Prospective evaluation of the Accelerate PhenoTest™ BC Kits in the Accelerate Pheno™ system (version 1.1) for reducing identification and antimicrobial susceptibility test turn-around time (ID-AST-TAT) of gram-negative bacilli (GNB) from positive blood cultures (+BC) incubated in bioMérieux Bact/Alert 3D system.* Presented by Susan Poutaneng, MD, MPH, FRCPC, and associate professor of microbiology Mount Sinai Hospital.

(cont.)

(Page 2/Cont.)

SERIAL NO: 0166/PROG. NO: PF45 — *Retrospective evaluation of the Accelerate PhenoTest™ BC kits in the Accelerate Pheno™ system (version 1.1.1) for identification and antimicrobial susceptibility testing (ID-AST) of gram-negative bacilli (GNB) including carbapenemase-producing organisms (CPO) from seeded blood culture bottles (SBCB) incubated in bioMérieux BacT/Alert 3D system.* Presented by Susan Poutaneng, MD, MPH, FRCPC, and associate professor of microbiology Mount Sinai Hospital.

SERIAL NO: 0167/PROG. NO: PF46 — *Comparison of the Accelerate PhenoTest™ BC identification and antimicrobial susceptibility test (ID-AST) results after simultaneous parallel incubations in bioMérieux BacT/Alert 3D and virtuO systems of gram-negative bacilli (GNB) seeded to blood culture bottles (SBCB).* Presented by Susan Poutaneng, MD, MPH, FRCPC, and associate professor of microbiology Mount Sinai Hospital.

SERIAL NO: 0225/PROG. NO: PF61 — *Impact of rapid identification and phenotypic antimicrobial susceptibility testing by the Accelerate Pheno™ system on time to antimicrobial (ABX) tailoring for gram-negative bacilli (GNB) bloodstream infections (BSI).* Presented by Susan Poutanen, MD, MPH, FRCPC and associate professor of microbiology Mount Sinai Hospital.

SERIAL NO: 0171/PROG. NO:PF62 — *Practical assessment of the Accelerate Pheno™ system's performance on growth from routine positive blood cultures.* Presented by Dr. Jennifer Grant BS, MD, CM (McGill University), and clinical associate professor and microbiologist, at Vancouver General Hospital.

SERIAL NO: 0249/PROG NO: PF63 — *Assessment of the Accelerate Pheno™ system for investigation of positive blood cultures in remote health care centers with a centralized off-site microbiology laboratory.* Presented by Dr. Jennifer Grant BS, MD, CM (McGill University), and clinical associate professor and microbiologist at Vancouver General Hospital.

SERIAL NO: 0079/PROG NO: PF16 — *Utilizing quality tools with key stakeholders to make the business case for a fast blood culture diagnostics platform with ID and antibiotic sensitivities with MICs in seven hours.* Presented by Maureen P. Spencer, M.Ed, RN, CIC, FAPIC; director, clinical implementation, Accelerate Diagnostics, Inc..

(cont.)

(Page 3/Cont.)

**About Accelerate Diagnostics, Inc.**

Accelerate Diagnostics, Inc. (NASDAQ:[AXDX](#)), is an *in vitro* diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and healthcare-associated infections. The company recently obtained FDA marketing authorization for antimicrobial susceptibility testing direct from positive blood culture samples using its Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit. The system and kit leverage proprietary molecular identification methods and morphokinetic cellular analysis (MCA) to provide minimum inhibitory concentrations for a range of applicable antibiotics. The fully-automated system is designed to eliminate the lengthy culture and sample preparation steps required prior to antimicrobial susceptibility testing. Recent studies suggest the solution offers results 1-2 days faster than conventional methods, enabling clinicians to optimize antibiotic selection, dosage and infusion strategy specific to the individual patient and their infection.

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond-shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.

Learn more or register to attend these events at: <http://www.cacmid.ca>

-###-